If I recall correctly, in late summer, I believe the FDA Comish Hahn came out and said (paraphrasing), "if a drug can reduce mortality by 35%, that is huge, and would be approved." We all remember the approval that convalescent plasma received and Hahn originally touted the exact reference of 35% reduction (which he corrected later and lowered). So, with a hypothetical 34.7% reduction in deaths, I would think leronlimab would be a lock for EUA or full approval. No way the FDA turns up their nose because of 0.3%, not as this pandemic rages and could possibly get worse over the next month or two!!